Oragenics, Inc. Files 10K and Provides Company Update
Oragenics, Inc. Files 10K and Provides Company Update
Oragenics, Inc. Files 10K and Provides Company Update
Oragenics, Inc. 提交了 10K 文件並提供公司最新情況
SARASOTA, Fla.--(BUSINESS WIRE)-- Oragenics, Inc. (the "Company") (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it has filed its annual report on March 29, 2024. The Company is pleased to report it has executed on its strategy to diversify its product development portfolio and makes progress in transforming the Company to create long term value. Some key items that have helped to improve the Company moving forward are:
佛羅里達州薩拉索塔--（美國商業資訊）--專注於開發用於治療神經系統疾病的獨特鼻內藥物的公司Oragenics, Inc.（“公司”）（紐約證券交易所美國股票代碼：OGEN）今天宣佈，已於2024年3月29日提交年度報告。該公司高興地報告，它已經執行了多元化產品開發組合的戰略，並在公司轉型以創造長期價值方面取得了進展。一些有助於改善公司前進的關鍵項目是：
- The Company acquired a platform technology intended to treat multiple neurological disorders. The first target indication is for concussion and the technology has successfully completed a Phase I trial.
- Raised approximately $ 2.1 million in a public offering and $890,000 in a private transaction.
- Hired a Chief Medical Officer: Dr James Kelly MD, is a thought leader in brain injury including concussion.
- Added two new Board members: John Gandolfo and Bruce Cassidy.
- Created a subsidiary in Australia to take advantage of R&D rebates offered by the Australian government.
- Contracted with a leading Contract Research Organization to oversee our Phase II clinical trial.
- Manufacturing drug in preparation for our Phase II trial.
- 該公司收購了一項旨在治療多種神經系統疾病的平台技術。第一個目標適應症是腦震盪，該技術已成功完成I期試驗。
- 通過公開募股籌集了約210萬美元，通過私人交易籌集了890,000美元。
- 聘請首席醫療官：醫學博士詹姆斯·凱利博士是包括腦震盪在內的腦損傷領域的思想領袖。
- 增加了兩名新的董事會成員：約翰·甘道夫和布魯斯·卡西迪。
- 在澳大利亞成立了一家子公司，以利用澳大利亞政府提供的研發折扣。
- 與一家領先的合同研究組織簽約，監督我們的二期臨床試驗。
- 製造藥物，爲我們的二期試驗做準備。
We are excited about the progress the Company has made in the past several months. We are creating a team with the experience and drive to further our neurological drug candidates through clinical trials during 2024," commented Michael Redmond, President of Oragenics.
我們對公司在過去幾個月中取得的進展感到興奮。Oragenics總裁邁克爾·雷德蒙德評論說，我們正在組建一支具有豐富經驗和動力的團隊，通過臨床試驗進一步發展我們的神經系統候選藥物。
As previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2023, which was filed on March 29, 2024 with the Securities and Exchange Commission, the audited consolidated financial statements contained an unqualified audit opinion from its independent registered public accounting firm that included an explanatory paragraph related to the Company's ability to continue as a going concern. See further discussion in footnote 1 of the Company's consolidated financial statements included in the Company's Annual Report on Form 10-K.
正如先前在2024年3月29日向美國證券交易委員會提交的截至2023年12月31日的10-K表年度報告中披露的那樣，經審計的合併財務報表包含其獨立註冊會計師事務所的無保留審計意見，其中包括與公司繼續經營能力有關的解釋性段落。請參閱公司10-K表年度報告中公司合併財務報表腳註1中的進一步討論。
About Oragenics
關於 Oragenics
Oragenics is a development-stage biotechnology company focused on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (mTBI), also known as concussion, and for treating Niemann Pick Disease Type C (NPC), as well as proprietary powder formulation and an intranasal delivery device. For more information, please visit www.oragenics.com.
Oragenics是一家處於開發階段的生物技術公司，專注於神經病學和對抗傳染病藥物的鼻腔輸送，包括用於治療輕度創傷性腦損傷（mtBI）（也稱爲腦震盪）和治療C型尼曼·皮克病（NPC）的候選藥物，以及專有的粉末配方和鼻內輸送設備。欲了解更多信息，請訪問 www.oragenics.com。
Forward-Looking Statements
前瞻性陳述
This communication contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management's beliefs and assumptions and information currently available. The words "believe," "expect," "anticipate," "intend," "estimate," "project" and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to those described in our Form 10-K and other filings with the U.S. Securities and Exchange Commission. All information set forth in this press release is as of the date hereof. You should consider these factors in evaluating the forward-looking statements included in this press release and not place undue reliance on such statements. We do not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by law.
本通信包含《1995年美國私人證券訴訟改革法》安全港條款所指的 “前瞻性陳述”。這些前瞻性陳述基於管理層的信念、假設和當前可用的信息。“相信”、“期望”、“預測”、“打算”、“估計”、“項目” 等詞以及不只與歷史問題相關的類似表述可識別前瞻性陳述。投資者在依賴前瞻性陳述時應謹慎行事，因爲前瞻性陳述受到各種風險、不確定性和其他因素的影響，這些因素可能導致實際業績與任何此類前瞻性陳述中表達的業績存在重大差異。這些因素包括但不限於我們在10-K表格和向美國證券交易委員會提交的其他文件中描述的因素。本新聞稿中列出的所有信息均截至本新聞稿發佈之日。在評估本新聞稿中包含的前瞻性陳述時，您應考慮這些因素，不要過分依賴此類陳述。除非法律另有規定，否則如果情況發生變化，我們不承擔任何義務公開對任何前瞻性陳述進行修訂或更新，無論是由於新信息、未來發展還是其他原因。
View source version on businesswire.com: https://www.businesswire.com/news/home/20240328369604/en/
在 businesswire.com 上查看源版本： https://www.businesswire.com/news/home/20240328369604/en/
Oragenics, Inc.
Janet Huffman, Chief Financial Officer
813-286-7900
jhuffman@oragenics.com
Oragenics, Inc.
珍妮特·霍夫曼，首席財務官
813-286-7900
jhuffman@oragenics.com
LHA Investor Relations
Tirth T. Patel
212-201-6614
tpatel@lhai.com
LHA 投資者關係
Tirth T. Patel
212-201-6614
tpatel@lhai.com
Source: Oragenics, Inc.
資料來源：Oragenics, Inc.
Released April 1, 2024
2024 年 4 月 1 日發佈
譯文內容由第三人軟體翻譯。